Ionis Pharmaceuticals Inc. (IONS) and Fortress Biotech Inc. (NASDAQ:FBIOP) Contrasting side by side

As Biotechnology businesses, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Fortress Biotech Inc. (NASDAQ:FBIOP), are affected by compare. This especially applies to their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals Inc. 568.84M 14.13 65.45M 0.51 104.36
Fortress Biotech Inc. 228.27M 0.63 69.68M -1.59 0.00

Table 1 demonstrates Ionis Pharmaceuticals Inc. and Fortress Biotech Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Ionis Pharmaceuticals Inc. and Fortress Biotech Inc.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals Inc. -11.51% -8.8% -2.4%
Fortress Biotech Inc. -30.53% 0% 0%

Institutional and Insider Ownership

Ionis Pharmaceuticals Inc. and Fortress Biotech Inc. has shares owned by institutional investors as follows: 89.5% and 0%. About 0.2% of Ionis Pharmaceuticals Inc.’s share are owned by insiders.

Performance

Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ionis Pharmaceuticals Inc. -8.51% -1.82% 19.71% 16.26% 1.5% 6.02%
Fortress Biotech Inc. -5.5% 3.75% -9.29% -24.55% 0% -27.03%

For the past year Ionis Pharmaceuticals Inc. has 6.02% stronger performance while Fortress Biotech Inc. has -27.03% weaker performance.

Summary

Ionis Pharmaceuticals Inc. beats Fortress Biotech Inc. on 9 of the 11 factors.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.